Sarcomatoid renal cell carcinoma
diseaseOn this page
Also known as RCC w/ sarcomatoid featuresrenal cell carcinoma with sarcomatoid featuressarcomatoid renal cell cancerSRCC
Summary
Sarcomatoid renal cell carcinoma (MONDO:0003012) is a cancer and 22 clinical trials. Top therapeutic interventions include nivolumab, cabozantinib, and pazopanib hydrochloride. A subtype of renal cell adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 22
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | sarcomatoid renal cell carcinoma |
| Mondo ID | MONDO:0003012 |
| DOID | DOID:4473 |
| NCIT | C27893 |
| UMLS | C1266043 |
| MedGen | 220411 |
| GARD | 0023327 |
| Is cancer (heuristic) | yes |
Also known as: RCC w/ sarcomatoid features · renal cell carcinoma with sarcomatoid features · sarcomatoid renal cell cancer · sarcomatoid renal cell carcinoma · SRCC
Data availability: 4 cell lines.
Disease family
This is a subtype of renal cell adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › renal cell carcinoma › renal cell adenocarcinoma › sarcomatoid renal cell carcinoma
Related subtypes (8): childhood kidney cell carcinoma, hereditary renal cell carcinoma, clear cell renal carcinoma, renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions, papillary renal cell carcinoma, chromophobe renal cell carcinoma, renal cell carcinoma associated with neuroblastoma, tubulocystic renal cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 22.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE1 | 7 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03055013 | PHASE3 | ACTIVE_NOT_RECRUITING | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy |
| NCT03793166 | PHASE3 | ACTIVE_NOT_RECRUITING | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study |
| NCT03541902 | PHASE2 | ACTIVE_NOT_RECRUITING | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma |
| NCT03866382 | PHASE2 | RECRUITING | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
| NCT05808608 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma |
| NCT06447103 | PHASE2 | RECRUITING | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer |
| NCT06866262 | PHASE1/PHASE2 | RECRUITING | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial |
| NCT07037004 | PHASE2 | NOT_YET_RECRUITING | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery |
| NCT07218692 | PHASE2 | NOT_YET_RECRUITING | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy |
| NCT00068393 | PHASE2 | COMPLETED | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma |
| NCT00126503 | PHASE1/PHASE2 | COMPLETED | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer |
| NCT01664182 | PHASE2 | COMPLETED | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer |
| NCT01767636 | PHASE2 | COMPLETED | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer |
| NCT03177239 | PHASE2 | UNKNOWN | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) |
| NCT03685448 | PHASE2 | COMPLETED | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) |
| NCT02496208 | PHASE1 | ACTIVE_NOT_RECRUITING | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
| NCT05122546 | PHASE1 | ACTIVE_NOT_RECRUITING | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer |
| NCT06049576 | PHASE1 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma |
| NCT06399419 | PHASE1 | RECRUITING | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer |
| NCT07128680 | PHASE1 | RECRUITING | Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer |
| NCT03483883 | PHASE1 | TERMINATED | Avelumab/Gemcitabine in Sarcomatoid RCC |
| NCT04272034 | PHASE1 | TERMINATED | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NIVOLUMAB | 4 | 10 |
| CABOZANTINIB | 4 | 7 |
| PAZOPANIB HYDROCHLORIDE | 4 | 2 |
| SORAFENIB | 4 | 2 |
| TIVOZANIB | 4 | 2 |
| INULIN | 4 | 1 |
| IPILIMUMAB | 4 | 1 |
| PEGFILGRASTIM | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| CADONILIMAB | 3 | 1 |
| TREBANANIB | 3 | 1 |
| CHEMBL4215501 | 0 | 3 |
| CHEMBL4849721 | 0 | 3 |
| EXELIXIS | 0 | 3 |
| CHEMBL3109278 | 0 | 2 |
| CHEMBL3939307 | 0 | 1 |